Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.lmcmannaresearch.com
Number of Employees: -
Year Founded: 1996
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
LMC Clinical Research Inc. operates as a life science and tools company. It provides clinical trials services on diabetes and endocrine conditions outside of the LMC diabetes and endocrinology practices. It also provides clinical trials for oncology, cardiology, pulmonology, and medical devices that evaluate the health of the liver. LMC Clinical Research Inc. was formerly known as LMC Manna Research. The company was founded in 1996 and is based in Toronto, Canada. As of November 17, 2021, LMC Clinical Research Inc. operates as a subsidiary of IACT Health.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Kingsley, Jeffrey Kenneth
Chief Executive Officer
Teitelbaum, Nancy 
Director of Marketing
Aronson, Ronnie 
Chief Medical Officer
Venn, Karri 
President of Research


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
1929 Bayview Avenue Suite 106 | Toronto, ON | M4G 3E8 | Canada
Phone: 833-323-5646   Fax: 416-645-2930

Parent Company
Institute For The Advancement Of Clinical Trials, L.L.C.

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Trinity Hunt Partners, L.P.
May-31-2023
Minority
-
Growth
John Oakes, JR Gilley


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Aventiv Research, Inc.
Aventiv Research, Inc. provides clinical trials and medical research services. The company offers standard operating procedures, staffing, quality assurance, consultation, and auditing services. It provides clinical studies in the areas of acid reflux, acne, actinic keratosis, arthritis, asthma, atopic dermatitis, COPD, diabetes, high cholesterol, hypertension, infant formula, low testosterone, migraines, obesity, opioid-induced constipation, psoriasis, and women's clinical research. Aventiv Research, Inc. was formerly known as Columbus Clinical Research Inc. The company was incorporated in 2002 and is based in Columbus, Ohio. It has additional locations in Dublin, Ohio; Mesa, Arizona; and Erie, Pennsylvania. As of June 21, 2022, Aventiv Research, Inc. operates as a subsidiary of LMC Clinical Research Inc.

United States and Canada
Life Sciences Tools and Services
8.00
-
-
True North Clinical Research Incorporated
True North Clinical Research Incorporated provides research related services for aging and Alzheimer’s disease. The company was founded in 2006 and is based in New Minas, Canada. As of December 15, 2021, True North Clinical Research Incorporated operates as a subsidiary of LMC Manna Research.

United States and Canada
Life Sciences Tools and Services
5.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-31-2023
May-31-2023
Private Placement
Target
LMC Clinical Research Inc.
Trinity Hunt Partners, L.P.

-
Jun-21-2022
Jun-21-2022
Merger/Acquisition
Buyer
Aventiv Research, Inc.
LMC Clinical Research Inc.

-
Dec-15-2021
Dec-15-2021
Merger/Acquisition
Buyer
True North Clinical Research Incorporated
LMC Clinical Research Inc.

-
Nov-17-2021
Nov-17-2021
Merger/Acquisition
Target
LMC Clinical Research Inc.
Institute For The Advancement Of Clinical Trials, L.L.C.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-06-2023
Company Conference Presentations
LMC Clinical Research Inc. Presents at Global Site Solutions Summit, Oct-05-2023 through Oct-08-2023
May-31-2023
Private Placements
LMC Clinical Research Inc. announced that it has received funding from Trinity Hunt Partners, L.P.
Mar-28-2023
Strategic Alliances
MCI Onehealth and LMC Healthcare's Centricity Research to Accelerate Access and Delivery of Clinical Research
Jun-21-2022
M&A Transaction Closings
LMC Clinical Research Inc. acquired Aventiv Research, Inc.
Jan-19-2022
Strategic Alliances
IACT Health, LMC Manna Research and True North Clinical Research Join Forces to Become Centricity Research, North America's Integrated Research Site Organization


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kingsley, Jeffrey Kenneth
Chief Executive Officer
833-323-5646
416-645-2930

Teitelbaum, Nancy 
Director of Marketing
762-261-0993
416-645-2930
nteitelbaum@iacthealth.com
Aronson, Ronnie 
Chief Medical Officer
833-323-5646
416-645-2930

Venn, Karri 
President of Research
833-323-5646
416-645-2930

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
